Screener
Jazz Pharmaceuticals JAZZ Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Income (loss) before income tax expense (benefit) and equity in loss of investees | 299.2 | (109.8) |
| Income tax expense (benefit) | 6.1 | (17.8) |
| Equity in loss of investees | — | 0.5 |
| Net income (loss) | $293.1 | $(92.5) |
| Net income (loss) per ordinary share: | ||
| Basic | $4.73 | $(1.52) |
| Diluted | $4.43 | $(1.52) |
| Weighted-average ordinary shares used in per share calculations - basic | 61.9 | 61.0 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's net income?
- Jazz Pharmaceuticals (JAZZ) reported net income of $293.1M in Q1 2026.
- How has Jazz Pharmaceuticals's net income changed year-over-year?
- Jazz Pharmaceuticals's net income increased by 416.9% year-over-year, from -$92.5M to $293.1M.
- What is the long-term trend for Jazz Pharmaceuticals's net income?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's net income has grown at a 19.3% compound annual growth rate (CAGR), from -$329.67M to $560.12M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Jazz Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude